Search results
Results from the WOW.Com Content Network
Intermittent explosive disorder (IED), or episodic dyscontrol syndrome (EDS), is a mental and behavioral disorder characterized by explosive outbursts of anger or violence, often to the point of rage, that are disproportionate to the situation at hand (e.g., impulsive shouting, screaming, or excessive reprimanding triggered by relatively inconsequential events).
This is a list of investigational aggression drugs, or drugs that are currently under development for clinical use in the treatment of aggression but are not yet approved. Drugs used to treat aggression may also be known as "serenics". [1]
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V 1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders.
Intermittent explosive disorder or IED is a clinical condition of experiencing recurrent aggressive episodes that are out of proportion of any given stressor. Earlier studies reported a prevalence rate between 1–2% in a clinical setting, however a study done by Coccaro and colleagues in 2004 had reported about 11.1% lifetime prevalence and 3. ...
People over the disorder's minimum age of 6 may be diagnosed with intermittent explosive disorder without outbursts of physical aggression. [11] Criteria were added for frequency and to specify "impulsive and/or anger based in nature, and must cause marked distress, cause impairment in occupational or interpersonal functioning, or be associated ...
Intermittent explosive disorder; P. Portrait of a Kleptomaniac; U. Utilization behavior This page was last edited on 3 September 2022, at 19:28 (UTC). Text is ...
Ross W. Greene is an American clinical child psychologist. The author of several books on child behavior—including The Explosive Child, Lost at School, Lost & Found, and Raising Human Beings—Greene originated the evidence-based Collaborative & Proactive Solutions (CPS) model of intervention.
Comorbidity complicates research design and clinical decision-making, as additional conditions can distort study results and affect treatment (i.e. researching the specific causes of a condition like major depressive disorder is complicated when many study participants will meet criteria for additional syndromes). In terms of classification ...